Tier 2 — strong

Oral nicotinamide riboside raises NAD+ and lowers biomarkers of neurodegenerative pathology in plasma extracellular vesicles enriched for neuronal origin

Vreones M, Mustapic M, Moaddel R, Pucha KA, Lovett J, Seals DR, Kapogiannis D, Martens CR
Aging cell 2023 22; 1; e13754

Bibliography

PubMed
PMID 36515353
PubMed Central
PMC9835564
DOI
10.1111/acel.13754
Funding
NIH/NIA support; the parent trial also received Glenn Foundation/AFAR support, and ChromaDex supplied NR and placebo.
Competing interests
The authors reported no competing interests.

Study snapshot

DesignSecondary or companion analysis of an existing human intervention
ModelHuman participants
Sample22 older adults from a prior randomized crossover trial
InterventionNR 500 mg twice daily versus placebo
Duration6 weeks per treatment period
EndpointsVesicle NAD+; Aβ42; signaling proteins

What the study showed, in plain terms

NR changed NAD+ and selected neurodegeneration-related proteins in plasma extracellular vesicles enriched for neuronal origin.

Key findings

Vesicle Aβ42, pJNK and pERK1/2 levels decreased.

What this study can and cannot tell us

Companion analysis of the older-adult trial, not a new clinical cohort. Blood vesicle enrichment is an indirect brain measure and does not establish cognitive benefit.

Related papers in the corpus

Tier 2
Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD + in healthy middle-aged and older adults
Martens CR et al. · Nature communications · 2018
Tier 2
A phase-II randomized controlled pilot study of nicotinamide riboside supplementation in older adults with amnestic mild cognitive impairment
Martens CR et al. · Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
Tier 2
Cognitive and Alzheimer's disease biomarker effects of oral nicotinamide riboside (NR) supplementation in older adults with subjective cognitive decline and mild cognitive impairment
Wu CY et al. · Alzheimer's & dementia (New York, N. Y.) · 2025
Tier 2
Effects of nicotinamide riboside on NAD+ levels, cognition, and symptom recovery in long-COVID: a randomized controlled trial
Wu CY et al. · EClinicalMedicine · 2025
Tier 2
A randomized placebo-controlled trial of nicotinamide riboside in older adults with mild cognitive impairment
Orr ME et al. · GeroScience · 2024

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology